Showing results (1-10 of 226) with videos related to

Sort By:
Pageof 23
The American Journal of Clinical Nutrition|January 30, 1999
Early childhood anemia and mild or moderate mental retardationE K Hurtado, A H Claussen, K G Scott
Clinical Pharmacology and Therapeutics|December 23, 2017
Development and Qualification of a Drug-Disease Modeling Platform to Characterize Clinically Relevant Endpoints in Type 2 Diabetes TrialsPuneet Gaitonde, Felipe K Hurtado, Parag Garhyan, et al.
Antimicrobial Agents and Chemotherapy|November 13, 2013
Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysisFelipe K Hurtado, Benjamin Weber, Hartmut Derendorf, et al.
International Journal of Antimicrobial Agents|September 15, 2014
Enhanced penetration of moxifloxacin into rat prostate tissue evidenced by microdialysisFelipe K Hurtado, João Victor Laureano, Graziela de A Lock, et al.
Journal of AOAC International|July 16, 2010
Validated stability-indicating RP-HPLC method for the determination of rimonabant in a pharmaceutical dosage formFelipe K Hurtado, Aline Ravanello, Marcela Z Arend, et al.
Biomedical Chromatography : BMC|June 3, 2020
Development and validation of an LC-MS/MS method for the quantitative analysis of the adenosine A2a receptor antagonist NIR178 and its monohydroxy metabolite in human plasma: Application to clinical pharmacokineticsOlivier Heudi, Nathalie Plaud, Celine Aumonier, et al.
Journal of the International Society of Sports Nutrition|December 7, 2017
Effects of two pre-workout supplements on concentric and eccentric force production during lower body resistance exercise in males and females: a counterbalanced, double-blind, placebo-controlled trialGrant M Tinsley, Matthew A Hamm, Amy K Hurtado, et al.
Cancer Chemotherapy and Pharmacology|January 4, 2021
Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumorsFelipe K Hurtado, Filippo de Braud, Javier De Castro Carpeño, et al.
The Lancet. Oncology|November 15, 2021
Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion studyMatthias Fischer, Lucas Moreno, David S Ziegler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2022
Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung CancerAlberto A Chiappori, Ben Creelan, Tawee Tanvetyanon, et al.
Pageof 23